1. Fertility preservation in patients with gynaecologic malignancy: Response to ovarian stimulation and long-term outcomes.
- Author
-
Tsonis, Orestis and Kopeika, Julia
- Subjects
- *
INDUCED ovulation , *FERTILITY preservation , *HUMAN reproductive technology , *GYNECOLOGIC cancer , *VAGINAL cancer , *FERTILITY clinics , *OVARIAN cancer - Abstract
• Efficacy and safety of controlled ovarian stimulation in patients presenting with gynaecologic malignancies for the purposes of fertility preservation has been underreported. • Theoretical concerns of such modality arise from the nature of the disease with regards to the location of the tumour and the anticipated hormonal sensitivity that some gynaecologic malignancies manifest. • To date, largest study reporting long- term outcomes following non-surgical FP treatment in patients with gynaecologic malignancies, including mortality rates and reproductive outcomes for this group of patients following non-surgical FP with ovarian stimulation. • Although data is limited, our results so far do not raise concerns when compared with national expected survival rates. To the best of our knowledge, the available evidence on the effect and efficacy of controlled ovarian stimulation (COS) in this group of patients remains poorly reported. Concerns related to the impact of stimulation to cancer progression and recurrence, as well as the risk of disease dissemination during egg collection, might explain the aforementioned trend. Overall, our FP Service received 192 gynaecological referrals, between 2005 and 2021, regarding gynaecologic conditions mainly cancer related. A total of 68 (35.4%) patients underwent COS. These patients were diagnosed with the following gynaecologic pathologies: 33 cases (48,5%) of cervical cancer were noted (stage 1b1-2b), 25 ovarian pathology (36.7%), 9 cases (13.2%) of endometrial cancer, and a single case of vaginal cancer (1.5%). The mean age of patients attending the fertility preservation service was 31.5 (std 5.8). The patients presenting to their initial appointment with a mean BMI 24.5 (IQR 6.9) and a median AFC of 12 (IQR 13). The mean duration of COS was 11 days (IQR 3), and the median dose of gonadotrophins was calculated at 300 IU (IQR 75 IU). In 95.4% of the cases, GnRH agonist was used as a trigger for final maturation. The median number of follicles measuring more than 14 mm at the time of trigger was 11 (IQR 8), whereas the median number of oocytes collected was 11 (IQR 9). The complication rate was reported at less than 2%. So far, one in four women of this FP group (17/68, 25% of the overall group) returned to our service to claim their cryopreserved eggs/embryos and successful livebirths were reported in 58.8% of this sample (10/17 cases). The mean time to return to use their oocytes/embryos was 36 months (min value 16 months – max value 85 months). There was no significant difference in mortality rate between patients who received FP vs those who did not (hazard ratio of mortality was estimated at 0.91 (p-value 0.88)). Based on our findings, ovarian stimulation for patients presenting with gynaecologic malignancy is a safe and efficient method of fertility preservation. Undoubtedly, the sample size is limited, however our results are reassuring and highlight the efficacy of COS for the purpose of FP based on data coming from the largest Assisted Conception Unit of the South-East of the UK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF